Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CERS
CERS logo

CERS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.930
1 Day change
-5.85%
52 Week Range
2.960
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cerus Corp (CERS) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While the technical indicators show some bullish signs, the lack of positive catalysts, insider selling, and weak financial performance make this stock a hold rather than a buy. The investor's long-term strategy and risk tolerance do not align with the current uncertainties surrounding this stock.

Technical Analysis

The MACD is positive at 0.0369, indicating a bullish momentum, but it is contracting. The RSI is neutral at 69.941, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 1.952, R1: 2.084, and S1: 1.821. The stock has a 70% chance to decrease by -0.8% in the next day, a 0.68% increase in the next week, and a 4.1% increase in the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • No significant positive catalysts identified. The stock has bullish moving averages and a slight chance of a 4.1% increase in the next month.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 2149.61% increase in selling activity over the last month. The company has no recent news or event-driven catalysts. Financial performance shows declining net income and gross margin.

Financial Performance

In Q4 2025, revenue increased by 13.79% YoY to $64.58M. However, net income dropped by -13.37% YoY to -$2.18M, and gross margin fell by -3.54% YoY to 56.64%. EPS remained flat at -0.01.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is provided.

Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
Wall Street analysts forecast CERS stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.930
sliders
Low
4
Averages
4.5
High
5
Current: 1.930
sliders
Low
4
Averages
4.5
High
5
TD Cowen
TD Cowen
Buy
maintain
$5
AI Analysis
2025-12-23
Reason
TD Cowen
TD Cowen
Price Target
$5
AI Analysis
2025-12-23
maintain
Buy
Reason
TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.

People Also Watch